Published in Cancer Res on January 15, 2003
Cancer drug resistance: an evolving paradigm. Nat Rev Cancer (2013) 6.77
Src kinases as therapeutic targets for cancer. Nat Rev Clin Oncol (2009) 4.07
Endothelial barrier disruption by VEGF-mediated Src activity potentiates tumor cell extravasation and metastasis. J Cell Biol (2004) 3.47
Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: results from the BELA trial. J Clin Oncol (2012) 2.90
Src blockade stabilizes a Flk/cadherin complex, reducing edema and tissue injury following myocardial infarction. J Clin Invest (2004) 2.48
Bcr-Abl stabilizes beta-catenin in chronic myeloid leukemia through its tyrosine phosphorylation. EMBO J (2007) 2.11
SRC-family kinases are activated in non-small cell lung cancer and promote the survival of epidermal growth factor receptor-dependent cell lines. Am J Pathol (2007) 1.79
SRC: a century of science brought to the clinic. Neoplasia (2010) 1.58
Src family kinase oncogenic potential and pathways in prostate cancer as revealed by AZD0530. Oncogene (2008) 1.57
Molecular mechanisms of acquired resistance to tyrosine kinase targeted therapy. Mol Cancer (2010) 1.56
Specific cross-talk between epidermal growth factor receptor and integrin alphavbeta5 promotes carcinoma cell invasion and metastasis. Cancer Res (2009) 1.44
Retinal vascular permeability suppression by topical application of a novel VEGFR2/Src kinase inhibitor in mice and rabbits. J Clin Invest (2008) 1.39
Breast cancer resistance protein (BCRP/ABCG2): its role in multidrug resistance and regulation of its gene expression. Chin J Cancer (2011) 1.30
Chronic myeloid leukemia stem cells in the era of targeted therapies: resistance, persistence and long-term dormancy. Oncotarget (2011) 1.27
SKI-606 (bosutinib), a novel Src kinase inhibitor, suppresses migration and invasion of human breast cancer cells. Mol Cancer Ther (2008) 1.23
Therapeutic targeting of the prostate cancer microenvironment. Nat Rev Urol (2010) 1.22
Structural and spectroscopic analysis of the kinase inhibitor bosutinib and an isomer of bosutinib binding to the Abl tyrosine kinase domain. PLoS One (2012) 1.17
Cooperation between VEGF and beta3 integrin during cardiac vascular development. Blood (2006) 1.17
The role of cooperativity with Src in oncogenic transformation mediated by non-small cell lung cancer-associated EGF receptor mutants. Oncogene (2009) 1.16
FoxO tumor suppressors and BCR-ABL-induced leukemia: a matter of evasion of apoptosis. Biochim Biophys Acta (2007) 1.13
Phosphoproteomics in cancer. Mol Oncol (2010) 1.12
Functions of the Lyn tyrosine kinase in health and disease. Cell Commun Signal (2012) 1.11
TSLP signaling network revealed by SILAC-based phosphoproteomics. Mol Cell Proteomics (2012) 1.04
EGFR-mediated carcinoma cell metastasis mediated by integrin αvβ5 depends on activation of c-Src and cleavage of MUC1. PLoS One (2012) 1.00
SKI-606, an Src inhibitor, reduces tumor growth, invasion, and distant metastasis in a mouse model of thyroid cancer. Clin Cancer Res (2012) 0.99
The Bcr-Abl tyrosine kinase inhibitor imatinib and promising new agents against Philadelphia chromosome-positive leukemias. Int J Clin Oncol (2007) 0.98
Identification of a Src tyrosine kinase/SIAH2 E3 ubiquitin ligase pathway that regulates C/EBPδ expression and contributes to transformation of breast tumor cells. Mol Cell Biol (2011) 0.97
Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukaemia: results from the 24-month follow-up of the BELA trial. Br J Haematol (2014) 0.97
P-loop mutations and novel therapeutic approaches for imatinib failures in chronic myeloid leukemia. J Hematol Oncol (2008) 0.95
Suboptimal response to or failure of imatinib treatment for chronic myeloid leukemia: what is the optimal strategy? Mayo Clin Proc (2009) 0.94
LRIG1 modulates cancer cell sensitivity to Smac mimetics by regulating TNFα expression and receptor tyrosine kinase signaling. Cancer Res (2012) 0.91
Role of tyrosine-kinase inhibitors in myeloproliferative neoplasms: comparative lessons learned. Onco Targets Ther (2016) 0.88
Induced protein degradation: an emerging drug discovery paradigm. Nat Rev Drug Discov (2016) 0.88
Drosophila Abelson kinase mediates cell invasion and proliferation through two distinct MAPK pathways. Oncogene (2010) 0.88
NS-187 (INNO-406), a Bcr-Abl/Lyn dual tyrosine kinase inhibitor. Anal Chem Insights (2007) 0.86
Profile of bosutinib and its clinical potential in the treatment of chronic myeloid leukemia. Onco Targets Ther (2013) 0.84
c-Src inactivation reduces renal epithelial cell-matrix adhesion, proliferation, and cyst formation. Am J Physiol Cell Physiol (2011) 0.83
Bosutinib inhibits migration and invasion via ACK1 in KRAS mutant non-small cell lung cancer. Mol Cancer (2014) 0.82
Hematopoietic cell kinase (HCK) as a therapeutic target in immune and cancer cells. Oncotarget (2015) 0.82
Development of novel ACK1/TNK2 inhibitors using a fragment-based approach. J Med Chem (2015) 0.82
Allografting for Bosutinib, Imatinib, Nilotinib, Dasatinib, and Interferon Resistant Chronic Myeloid Leukemia without ABL Kinase Mutation. Case Rep Hematol (2011) 0.81
Elevated expression of long intergenic non-coding RNA HOTAIR in a basal-like variant of MCF-7 breast cancer cells. Mol Carcinog (2014) 0.81
Ever-advancing chronic myeloid leukemia treatment. Int J Clin Oncol (2013) 0.81
Design of substrate-based BCR-ABL kinase inhibitors using the cyclotide scaffold. Sci Rep (2015) 0.80
Bosutinib in the treatment of patients with Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia: an overview. Ther Adv Hematol (2014) 0.79
Practical management of patients with chronic myeloid leukemia who develop tyrosine kinase inhibitor-resistant BCR-ABL1 mutations. Ther Adv Hematol (2014) 0.78
Bosutinib in the management of chronic myelogenous leukemia. Biologics (2013) 0.78
Targeted treatment of imatinib-resistant chronic myeloid leukemia: Focus on dasatinib. Onco Targets Ther (2009) 0.78
In vitro and in vivo identification of ABCB1 as an efflux transporter of bosutinib. J Hematol Oncol (2015) 0.78
Monitoring response and resistance to treatment in chronic myeloid leukemia. Curr Oncol (2011) 0.76
Molecular interactions of c-ABL mutants in complex with imatinib/nilotinib: a computational study using linear interaction energy (LIE) calculations. J Mol Model (2012) 0.76
Phase 2 study of bosutinib, a Src inhibitor, in adults with recurrent glioblastoma. J Neurooncol (2014) 0.76
Pro32Pro33 mutations in the integrin β3 PSI domain result in αIIbβ3 priming and enhanced adhesion: reversal of the hypercoagulability phenotype by the Src inhibitor SKI-606. Mol Pharmacol (2014) 0.76
Bosutinib for Chronic Myeloid Leukemia. Rare Cancers Ther (2015) 0.75
Imatinib resistance: a review of alternative inhibitors in chronic myeloid leukemia. Rev Bras Hematol Hemoter (2011) 0.75
Bosutinib reduces the efficacy of Dasatinib in triple-negative breast cancer cell lines. Anticancer Res (2014) 0.75
When will resistance be futile? Cancer Res (2014) 0.75
Chronic myeloid leukemia 2011: successes, challenges, and strategies--proceedings of the 5th annual BCR-ABL1 positive and BCR-ABL1 negative myeloproliferative neoplasms workshop. Am J Hematol (2011) 0.75
The Src kinases Hck, Fgr and Lyn activate Arg to facilitate IgG-mediated phagocytosis and Leishmania infection. J Cell Sci (2016) 0.75
Tubedown regulation of retinal endothelial permeability signaling pathways. Biol Open (2015) 0.75
Novel Src/Abl tyrosine kinase inhibitor bosutinib suppresses neuroblastoma growth via inhibiting Src/Abl signaling. Oncotarget (2016) 0.75
Tyrosine kinase-mediated axial motility of basal cells revealed by intravital imaging. Nat Commun (2016) 0.75
Chronic myeloid leukemia among patients with a history of prior malignancies: A tale of dual survivorship. Cancer (2016) 0.75
SFK/FAK signaling attenuates osimertinib efficacy in both drug-sensitive and drug-resistant models of EGFR-mutant lung cancer. Cancer Res (2017) 0.75
Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med (2012) 13.17
Effect on left ventricular function of intracoronary transplantation of autologous bone marrow mesenchymal stem cell in patients with acute myocardial infarction. Am J Cardiol (2004) 5.82
Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR/ABL mutants. J Clin Oncol (2008) 3.85
Ammonia derived from glutaminolysis is a diffusible regulator of autophagy. Sci Signal (2010) 3.38
Directed differentiation of human embryonic stem cells into functional hepatic cells. Hepatology (2007) 3.29
Biochemical, cellular, and in vivo activity of novel ATP-competitive and selective inhibitors of the mammalian target of rapamycin. Cancer Res (2009) 3.03
In vitro and in vivo activity of SKI-606, a novel Src-Abl inhibitor, against imatinib-resistant Bcr-Abl+ neoplastic cells. Cancer Res (2006) 2.72
The receptor tyrosine kinase inhibitor SU11248 impedes endothelial cell migration, tubule formation, and blood vessel formation in vivo, but has little effect on existing tumor vessels. Angiogenesis (2004) 1.87
Beyond rapalog therapy: preclinical pharmacology and antitumor activity of WYE-125132, an ATP-competitive and specific inhibitor of mTORC1 and mTORC2. Cancer Res (2010) 1.86
Identification and validation of novel androgen-regulated genes in prostate cancer. Endocrinology (2004) 1.76
Targeting vascular and avascular compartments of tumors with C. novyi-NT and anti-microtubule agents. Cancer Biol Ther (2004) 1.71
PWT-458, a novel pegylated-17-hydroxywortmannin, inhibits phosphatidylinositol 3-kinase signaling and suppresses growth of solid tumors. Cancer Biol Ther (2005) 1.70
Expression of myeloid-related protein-8 and -14 in patients with acute Kawasaki disease. J Am Coll Cardiol (2006) 1.65
Large scale comparison of gene expression levels by microarrays and RNAseq using TCGA data. PLoS One (2013) 1.61
A kinome-wide screen identifies the insulin/IGF-I receptor pathway as a mechanism of escape from hormone dependence in breast cancer. Cancer Res (2011) 1.53
Angiographic and clinical comparisons of intravascular ultrasound- versus angiography-guided drug-eluting stent implantation for patients with chronic total occlusion lesions: two-year results from a randomised AIR-CTO study. EuroIntervention (2015) 1.53
Stoichiometry of expressed KCNQ2/KCNQ3 potassium channels and subunit composition of native ganglionic M channels deduced from block by tetraethylammonium. J Neurosci (2003) 1.47
A Src/Abl kinase inhibitor, SKI-606, blocks breast cancer invasion, growth, and metastasis in vitro and in vivo. Cancer Res (2007) 1.45
Prognostic significance of differentially expressed miRNAs in esophageal cancer. Int J Cancer (2011) 1.43
In vivo antitumor effects of the mTOR inhibitor CCI-779 against human multiple myeloma cells in a xenograft model. Blood (2004) 1.43
Src inhibition ameliorates polycystic kidney disease. J Am Soc Nephrol (2008) 1.43
Diagnostic accuracy of quantitative angiographic and intravascular ultrasound parameters predicting the functional significance of single de novo lesions. Int J Cardiol (2012) 1.42
Final kissing balloon inflation by classic crush stenting did not improve the clinical outcomes for the treatment of unprotected left main bifurcation lesions: the importance of double-kissing crush technique. Catheter Cardiovasc Interv (2008) 1.41
NEMO trimerizes through its coiled-coil C-terminal domain. J Biol Chem (2002) 1.41
Mechanisms and clinical significance of quality of final kissing balloon inflation in patients with true bifurcation lesions treated by crush stenting technique. Chin Med J (Engl) (2009) 1.40
Functional genomic screens identify CINP as a genome maintenance protein. Proc Natl Acad Sci U S A (2009) 1.38
Cyclin-dependent kinase 9-cyclin K functions in the replication stress response. EMBO Rep (2010) 1.36
Fish, shellfish, and long-chain n-3 fatty acid consumption and risk of incident type 2 diabetes in middle-aged Chinese men and women. Am J Clin Nutr (2011) 1.32
Three-stage quality control strategies for DNA re-sequencing data. Brief Bioinform (2013) 1.30
SKI-606, a Src/Abl inhibitor with in vivo activity in colon tumor xenograft models. Cancer Res (2005) 1.29
Improvement of cardiac function after transplantation of autologous bone marrow mesenchymal stem cells in patients with acute myocardial infarction. Chin Med J (Engl) (2004) 1.28
A phase II study of celecoxib in combination with paclitaxel, carboplatin, and radiotherapy for patients with inoperable stage IIIA/B non-small cell lung cancer. Clin Cancer Res (2009) 1.27
Synthesis and SAR of [1,2,4]triazolo[1,5-a]pyrimidines, a class of anticancer agents with a unique mechanism of tubulin inhibition. J Med Chem (2007) 1.26
RNA interference (RNAi) screening approach identifies agents that enhance paclitaxel activity in breast cancer cells. Breast Cancer Res (2010) 1.25
SKI-606 (bosutinib), a novel Src kinase inhibitor, suppresses migration and invasion of human breast cancer cells. Mol Cancer Ther (2008) 1.23
EGF receptor tyrosine kinase inhibition attenuates the development of PKD in Han:SPRD rats. Kidney Int (2003) 1.22
Antitumor efficacy of PKI-587, a highly potent dual PI3K/mTOR kinase inhibitor. Clin Cancer Res (2011) 1.21
Inhibition of cancer cell proliferation and prostaglandin E2 synthesis by Scutellaria baicalensis. Cancer Res (2003) 1.20
Taz-tead1 links cell-cell contact to zeb1 expression, proliferation, and dedifferentiation in retinal pigment epithelial cells. Invest Ophthalmol Vis Sci (2010) 1.19
Hybrid inhibitors of phosphatidylinositol 3-kinase (PI3K) and the mammalian target of rapamycin (mTOR): design, synthesis, and superior antitumor activity of novel wortmannin-rapamycin conjugates. J Med Chem (2010) 1.17
Efficient internalization of silica-coated iron oxide nanoparticles of different sizes by primary human macrophages and dendritic cells. Toxicol Appl Pharmacol (2011) 1.16
Combination treatment of PKD utilizing dual inhibition of EGF-receptor activity and ligand bioavailability. Kidney Int (2003) 1.15
Myosin Ib modulates the morphology and the protein transport within multi-vesicular sorting endosomes. J Cell Sci (2005) 1.13
Antibody-targeted chemotherapy with CMC-544: a CD22-targeted immunoconjugate of calicheamicin for the treatment of B-lymphoid malignancies. Blood (2003) 1.12
Copper regulation of hypoxia-inducible factor-1 activity. Mol Pharmacol (2008) 1.12
Comparison between the NERS (New Risk Stratification) score and the SYNTAX (Synergy between Percutaneous Coronary Intervention with Taxus and Cardiac Surgery) score in outcome prediction for unprotected left main stenting. JACC Cardiovasc Interv (2010) 1.11
Spleens of myelofibrosis patients contain malignant hematopoietic stem cells. J Clin Invest (2012) 1.09
The establishment of a novel non-alcoholic steatohepatitis model accompanied with obesity and insulin resistance in mice. Life Sci (2008) 1.09
The use of next generation sequencing technology to study the effect of radiation therapy on mitochondrial DNA mutation. Mutat Res (2012) 1.09
Identification of a conserved sequence motif that promotes Cdc37 and cyclin D1 binding to Cdk4. J Biol Chem (2003) 1.08
Ligand-binding regulation of LXR/RXR and LXR/PPAR heterodimerizations: SPR technology-based kinetic analysis correlated with molecular dynamics simulation. Protein Sci (2005) 1.06
Validity and reliability of multiparameter physiological measurements recorded by the Equivital LifeMonitor during activities of various intensities. J Occup Environ Hyg (2013) 1.05
Genetic and pharmacologic inhibition of EPHA2 promotes apoptosis in NSCLC. J Clin Invest (2014) 1.03
Evaluation of read count based RNAseq analysis methods. BMC Genomics (2013) 1.03
Decreased PITX1 homeobox gene expression in human lung cancer. Lung Cancer (2006) 1.02
SKI-606 (Bosutinib) blocks prostate cancer invasion, growth, and metastasis in vitro and in vivo through regulation of genes involved in cancer growth and skeletal metastasis. Mol Cancer Ther (2010) 1.02
Effects of cancer-associated EPHA3 mutations on lung cancer. J Natl Cancer Inst (2012) 1.02
T-carbon: a novel carbon allotrope. Phys Rev Lett (2011) 1.02
Adverse effects of hyperlipidemia on bone regeneration and strength. J Bone Miner Res (2012) 1.01
Long-term tumor regression induced by an antibody-drug conjugate that targets 5T4, an oncofetal antigen expressed on tumor-initiating cells. Mol Cancer Ther (2012) 1.01
Efficacy and pharmacodynamic effects of bosutinib (SKI-606), a Src/Abl inhibitor, in freshly generated human pancreas cancer xenografts. Mol Cancer Ther (2009) 1.01
Biodegradation of single-walled carbon nanotubes by eosinophil peroxidase. Small (2013) 1.01
Synthesis and SAR of 6-chloro-4-fluoroalkylamino-2-heteroaryl-5-(substituted)phenylpyrimidines as anti-cancer agents. Bioorg Med Chem (2008) 1.00
Zeb1 represses Mitf and regulates pigment synthesis, cell proliferation, and epithelial morphology. Invest Ophthalmol Vis Sci (2009) 1.00
Using health literacy and learning style preferences to optimize the delivery of health information. J Health Commun (2012) 0.99
Proteomics, pathway array and signaling network-based medicine in cancer. Cell Div (2009) 0.99
Yes-associated protein expression in head and neck squamous cell carcinoma nodal metastasis. PLoS One (2011) 0.99
Five-year clinical follow-up of unprotected left main bifurcation lesion stenting: one-stent versus two-stent techniques versus double-kissing crush technique. EuroIntervention (2012) 0.98
Discovery of lactoquinomycin and related pyranonaphthoquinones as potent and allosteric inhibitors of AKT/PKB: mechanistic involvement of AKT catalytic activation loop cysteines. Mol Cancer Ther (2007) 0.98
Pegylated wortmannin and 17-hydroxywortmannin conjugates as phosphoinositide 3-kinase inhibitors active in human tumor xenograft models. J Med Chem (2006) 0.98
Inhibition of the signal transducer and activator of transcription-3 (STAT3) signaling pathway by 4-oxo-1-phenyl-1,4-dihydroquinoline-3-carboxylic acid esters. J Med Chem (2008) 0.97
Antiparallel coiled-coil-mediated dimerization of myosin X. Proc Natl Acad Sci U S A (2012) 0.96
Abrogation of constitutive Stat3 activity circumvents cisplatin resistant ovarian cancer. Cancer Lett (2013) 0.96
[DK crush technique: modified treatment of bifurcation lesions in coronary artery]. Chin Med J (Engl) (2005) 0.96
Interleukin-32beta propagates vascular inflammation and exacerbates sepsis in a mouse model. PLoS One (2010) 0.96
The INAD scaffold is a dynamic, redox-regulated modulator of signaling in the Drosophila eye. Cell (2011) 0.96
Acute Kawasaki disease is associated with reverse regulation of soluble receptor for advance glycation end products and its proinflammatory ligand S100A12. Arthritis Rheum (2007) 0.96
The CC1-FHA tandem as a central hub for controlling the dimerization and activation of kinesin-3 KIF1A. Structure (2012) 0.95
Indolyl-quinuclidinols inhibit ENOX activity and endothelial cell morphogenesis while enhancing radiation-mediated control of tumor vasculature. FASEB J (2009) 0.94
Inhibition of Src kinase activity by 7-[(2,4-dichloro-5-methoxyphenyl)amino]-2-heteroaryl-thieno[3,2-b]pyridine-6-carbonitriles. Bioorg Med Chem Lett (2005) 0.94
Discovery of a stable macrocyclic o-aminobenzamide Hsp90 inhibitor which significantly decreases tumor volume in a mouse xenograft model. Bioorg Med Chem Lett (2011) 0.94
Reduced expression of EphrinA1 (EFNA1) inhibits three-dimensional growth of HT29 colon carcinoma cells. Cancer Lett (2002) 0.94
Mild method for succinimide hydrolysis on ADCs: impact on ADC potency, stability, exposure, and efficacy. Bioconjug Chem (2014) 0.94
Antitumor efficacy profile of PKI-402, a dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor. Mol Cancer Ther (2010) 0.94